J&J and UnitedHealth raise FY26 outlooks after earnings
Question
J&J and UnitedHealth raise FY26 outlooks after earnings
Direct answer
Raised FY26 outlooks can support JNJ and UNH multiples and lift sector sentiment into the next trading session through healthcare earnings revisions.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-16
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-21
Cite as: Market Ontology, “J&J and UnitedHealth raise FY26 outlooks after earnings”, revision 1, evidence through 2026-10-16. https://marketontology.com/market-events/2026-10-16/j-j-and-unitedhealth-raise-fy26-outlooks-after-earnings-f77ed4
How this development reaches the affected companies
| Asset | Exposure and channel | Direction | Evidence |
|---|---|---|---|
| JNJ | raised FY26 outlook supports healthcare multiple expansion and earnings revisions | Up1-5d | Johnson & Johnson has raised its FY26 outlook following solid quarterly earnings. |
| UNH | raised FY26 outlook supports managed-care multiple support and earnings revisions | Up1-5d | UnitedHealth Group has raised its FY26 outlook following solid quarterly earnings. |
Does this development affect your holdings?
Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.
Review your initial audit before choosing ongoing portfolio scanning at $79/month.
What happened next
| Asset | Call | Base close | +1 day | +5 days | +20 days |
|---|---|---|---|---|---|
| JNJ | Up | 255.56 2026-10-16 | Pending | Pending | Pending |
| UNH | Upagreed | 401.43 2026-10-16 | +1.36% | Pending | Pending |
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related
- 2026-10-18J&J raises sales outlook, but MedTech weakness is in the tapeJNJ
- 2026-10-18UnitedHealth reiterates 13% to 16% growth target on 30% prior auth dropUNH XLV+1.36%
- 2026-10-18UnitedHealth reiterates 13% to 16% growth target on 30% prior auth dropUNH XLV+1.36%
- 2026-10-18Johnson & Johnson falls 6% on MedTech weakness despite full-year guidance raiseJNJ
- 2026-10-18Johnson & Johnson falls 6% on MedTech weakness despite full-year guidance raiseJNJ
- 2026-10-18UnitedHealth Reaffirms 13% to 16% Target as Q3 Prior Authorizations Fall 30%UNH XLV+1.36%
- 2026-10-18UnitedHealth reiterates 13-16% growth as AI cuts prior authorizations by 30%UNH XLV+1.36%
- 2026-10-18UnitedHealth Reaffirms 13% to 16% Target as Q3 Prior Authorizations Fall 30%UNH XLV+1.36%
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.